Table 2.
Laboratory and treatment characteristics
| All patients n = 32 (%) | Thrombosis n = 9 (%) | Non-trombotic n = 23 (%) | P value | |
|---|---|---|---|---|
| Prolonged aPTT | 30 (94%) | 9 (100%) | 21 (91%) | 0.36 |
| Value in seconds (NV = 33 s) | 77 (27-124 s) | 97 (41-124 s) | 69 (27–120) | 0.033* |
| Lupus anticoagulant (dRVVT) | 32 (100%) | 9 (100%) | 23 (100%) | |
| Value (NV = < 1.2) | 2.07 | 2.13 | 2.05 | 0.71 |
| Anticardiolipin antibodies | 29 (91%) | 8 (88%) | 21 (91%) | |
| IgG | 20 (63%) | 6 (66%) | 14 (61%) | 0.76 |
| Value (NV < 40) | 191 GPL | 188 GPL | 192 GPL | 0.86 |
| IgM | 19 (59%) | 4 (44%) | 15 (65%) | 0.28 |
| Value (NV < 40) | 153 MPL | 154 MPL | 153 MPL | 0.50 |
| Antibody profile | ||||
| LAC | 2 (6%) | 1 (11%) | 1 (4%) | 0.47 |
| LAC + ACL IgG | 10 (31%) | 4 (44%) | 6 (26%) | 0.31 |
| LAC + ACL IgM | 8 (25%) | 0 | 8 (35%) | 0.041* |
| LAC + ACL IgG + IgM | 9 (28%) | 2 (22%) | 7 (30%) | 0.64 |
| LAC + ACL IgM + B2GPI | 2 (6%) | 2 (22%) | 0 | |
| LAC + ACL IgG + B2GPI | 1 (3%) | 0 | 1 (4%) | |
| Treatment | ||||
| Anticoagulation | 9 (28%) | 9 (100%) | 0 | |
| Antiplatelet | 23 (72%) | 0 | 23 (100%) | |
| Steroid | 30 (94%) | 8 (88%) | 22 (96%) | |
| Immunosuppressant | 30 (94%) | 8 (88%) | 22 (96%) | |
| Cyclophosphamide | 8 (25%) | 6 (66%) | 2 (9%) | |
| Mycophenolate | 18 (56%) | 1 (11%) | 17 (74%) | |
| Azathioprine | 4 (13%) | 1 (11%) | 3 (13%) | |
| Rituximab | 4 (13%) | 2 (22%) | 2 (9%) | |
aPTT Activated partial thromboplastin time, LAC Lupus anticoagulant, ACL Anticardiolipin antibodies, NV Normal value, dRVVT Diluted Russell Viper Venom Time